Prevalence of olfactory dysfunction in D614G, alpha, delta and omicron waves: a psychophysical case-control study
- PMID: 36272169
- DOI: 10.4193/Rhin22.294
Prevalence of olfactory dysfunction in D614G, alpha, delta and omicron waves: a psychophysical case-control study
Abstract
Background: The purpose of this study was to compare the prevalence of olfactory dysfunction (OD) at different stages of the COVID-19 pandemic by evaluating subjects diagnosed with SARS-CoV-2 infection during the Omicron wave with psychophysical tests and comparing the results with those obtained from patients infected during the D614G, Alpha and Delta waves and with those of a control group.
Methodology: The study included adult patients diagnosed with SARS-CoV-2 infection. Depending on the time of diagnosis, the subjects were divided into four study groups: D614G; Alpha, Delta and Omicron variant groups. A group of uninfected individuals was used as control. All subjects underwent psychophysical evaluation of the olfactory function with the Connecticut Chemosensory Clinical Research Center olfactory test (D614G and Alpha groups) or the extended version of the Sniffin'Sticks test (Delta, Omicron and control groups).
Results: 372 cases (134 D614G group, 118 Alpha group, 32 in Delta group and 88 Omicron group) were recruited and evaluated within 10 days of infection, alongside 80 controls. Patients self-reported olfactory loss in 72.4% of cases in the D614G group, in 75.4% of cases in the Alpha group, in 65.6% of cases in the Delta group and in 18.1% in the Omicron group. Psychophysical evaluation revealed a prevalence of OD: 80.6%, 83.0%, 65.6% and 36.3% in the D614G, Alpha, Delta and Omicron group respectively. The differences between the D614G, Alpha and Delta groups were not statistically significant. The Omicron group demonstrated a significantly lower prevalence of OD than the other variants but still significantly higher than the controls.
Conclusions: During the Omicron wave OD was less prevalent than during the D614G, Alpha and Delta periods. One-third of patients have reduced olfactory function on psychophysical evaluation during the Omicron wave. Our results should be considered with caution as the VOC has not been determined with certainty.
Similar articles
-
The Omicron Variant BA.1.1 Presents a Lower Pathogenicity than B.1 D614G and Delta Variants in a Feline Model of SARS-CoV-2 Infection.J Virol. 2022 Sep 14;96(17):e0096122. doi: 10.1128/jvi.00961-22. Epub 2022 Aug 24. J Virol. 2022. PMID: 36000850 Free PMC article.
-
In vitro and in vivo differences in neurovirulence between D614G, Delta And Omicron BA.1 SARS-CoV-2 variants.Acta Neuropathol Commun. 2022 Sep 5;10(1):124. doi: 10.1186/s40478-022-01426-4. Acta Neuropathol Commun. 2022. PMID: 36058935 Free PMC article.
-
The Omicron variant BA.1.1 presents a lower pathogenicity than B.1 D614G and Delta variants in a feline model of SARS-CoV-2 infection.bioRxiv [Preprint]. 2022 Jun 16:2022.06.15.496220. doi: 10.1101/2022.06.15.496220. bioRxiv. 2022. Update in: J Virol. 2022 Sep 14;96(17):e0096122. doi: 10.1128/jvi.00961-22. PMID: 35734088 Free PMC article. Updated. Preprint.
-
The Molecular Basis of Olfactory Dysfunction in COVID-19 and Long COVID.Lifestyle Genom. 2024;17(1):42-56. doi: 10.1159/000539292. Epub 2024 May 15. Lifestyle Genom. 2024. PMID: 38749402 Review.
-
Olfactory Dysfunction: A Highly Prevalent Symptom of COVID-19 With Public Health Significance.Otolaryngol Head Neck Surg. 2020 Jul;163(1):12-15. doi: 10.1177/0194599820926464. Epub 2020 May 5. Otolaryngol Head Neck Surg. 2020. PMID: 32366160 Review.
Cited by
-
Do SARS-CoV-2 Variants Differ in Their Neuropathogenicity?mBio. 2023 Feb 28;14(1):e0292022. doi: 10.1128/mbio.02920-22. Epub 2023 Jan 18. mBio. 2023. PMID: 36651750 Free PMC article.
-
Symptom-based scoring technique by machine learning to predict COVID-19: a validation study.BMC Infect Dis. 2023 Dec 12;23(1):871. doi: 10.1186/s12879-023-08846-0. BMC Infect Dis. 2023. PMID: 38087249 Free PMC article.
-
Long-Term Taste and Smell Outcomes After COVID-19.JAMA Netw Open. 2024 Apr 1;7(4):e247818. doi: 10.1001/jamanetworkopen.2024.7818. JAMA Netw Open. 2024. PMID: 38652477 Free PMC article.
-
Long-term self-reported symptoms and psychophysical tests in COVID-19 subjects experiencing persistent olfactory dysfunction: a 4-year follow-up study.Front Neural Circuits. 2025 May 7;19:1538821. doi: 10.3389/fncir.2025.1538821. eCollection 2025. Front Neural Circuits. 2025. PMID: 40401088 Free PMC article.
-
Post-Viral Olfactory Loss: What We Learned from the SARS-CoV-2 Pandemic.Life (Basel). 2022 Nov 12;12(11):1868. doi: 10.3390/life12111868. Life (Basel). 2022. PMID: 36431003 Free PMC article.
MeSH terms
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous